A team led by David Kostin said that “a vaccine would likely catalyze another move higher in EPS estimates, particularly for cyclicals.”
Goldman Sachs says it’s optimistic the US stock market sell-off is almost over and keeps its 3,600 year-end target for the S&P 500
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push